最新消息 – 微菌叢研究中心

This study developed a deep learning–based **liver lesion localization and classification (DLLC)** system designed to assist physicians in interpreting focal hepatic lesions on CT images. The system achieved a mean average precision of **0.81** for lesion localization and a classification accuracy of **0.97**. Its accuracy was **0.83** for lesions with a diameter of less than 3 cm and **0.87** for lesions larger than 3 cm. This system provides an accurate and noninvasive diagnostic approach that is of significant value to hepatologists and radiologists.

October 22, 2024

July 30, 2024

Congratulations to Associate Professor Li-Lin Liang and colleagues on their article, “The Role of Digital Health Under Taiwan’s National Health Insurance System: Progress and Challenges,” being published in *Health Systems and Reform.

Congratulations to Professor Chun-Ying Wu and colleagues on their article, “Short-chain fatty acids ameliorate imiquimod-induced skin thickening and IL-17 levels and alter gut microbiota in mice: a metagenomic association analysis,” being published in Scientific Reports.

Digital health encompasses the application of digital technologies in the medical field and plays a crucial role in improving the accessibility, quality, and efficiency of healthcare services. This study examines digital health under Taiwan’s National Health Insurance system, particularly its impact during the COVID-19 pandemic, with a focus on big data management and analytics (such as MediCloud and My Health Bank/NHI Mobile Easy Access) as well as innovative service models (such as telemedicine). The findings indicate that individuals with higher incomes and those with chronic or severe illnesses are more likely to use telemedicine, and the study highlights the challenges of digital trust and the digital divide.

This study investigates the effects of short-chain fatty acids (SCFAs) on the skin phenotype, systemic inflammation, and gut microbiota of mice with psoriasis-like disease. Imiquimod (IMQ)-treated mice were used as a model, and a genomics approach was employed to analyze the effects of SCFAs or anti–IL-17 antibody on skin thickness, inflammatory markers, and fecal microbiota. The results showed that SCFAs improved IMQ-induced skin thickening, splenomegaly, and serum IL-17F levels, with effects comparable to anti–IL-17 therapy. SCFAs also increased microbial diversity and altered the composition of the gut microbiota, suggesting their involvement in processes such as carbohydrate degradation and phenylalanine metabolism.